Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.57 |
| ▸ | NPY2R | P49146 | 3/20 | 0.57 |
| ▸ | NPY4R | P50391 | 3/20 | 0.57 |
| ▸ | GHSR | Q92847 | 8/20 | 0.57 |
| ▸ | CCKBR | P32239 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 2/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849030 | 1.00 | NPY1R (0.57) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL29519296 | 0.95 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL30366588 | 0.95 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL30494060 | 0.94 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL29399016 | 0.90 | GHSR (0.68) | NPY1RNPY2RNPY4RGHSRKISS1R | |
| SCHEMBL29402231 | 0.90 | GHSR (0.69) | NPY1RNPY2RNPY4RGHSRKISS1R | |
| SCHEMBL29519677 | 0.87 | KISS1R (0.57) | NPY1RNPY2RNPY4RCCKBRKISS1R | |
| SCHEMBL30015333 | 0.85 | REN (0.53) | GHSR | |
| SCHEMBL29373777 | 0.84 | NPY1R (0.74) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL30051525 | 0.82 | CTSC (0.66) | GHSRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346998-B1 | TOPICAL FILM DELIVERY SYSTEM | SIDMAK LABORATORIES INDIA PVT LTD (IN) | 2025-04-16 | — | — | EP | disclosed |
| US-20240156856-A1 | NOVEL APPLICATIONS OF HYALURONIC ACID FOR TREATMENT OF PAIN AND PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-16 | — | — | US | disclosed |
| EP-3810106-B1 | COMPOSITION COMPRISING N-ACETYLCYSTEINE AND ANDROGRAPHOLIDE FOR USE IN THE PREVENTION AND/OR TREATMENT OF SENSORINEURAL HEARING LOSS OF THE INNER EAR | ALERE VITAM S R L (IT) | 2023-11-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156856-A1 | NOVEL APPLICATIONS OF HYALURONIC ACID FOR TREATMENT OF PAIN AND PRURITIS | CD44, TRPV1, HRH1 | NPY1R 213/4885NPY2R 464/4885NPY4R 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.